Format

Send to

Choose Destination
J Obes Weight Loss Medicat. 2015;1(1). pii: 004. Epub 2015 May 6.

Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports.

Author information

1
Department of Pediatrics, Division of Pediatric Endocrinology, Columbia University Medical Center, USA.

Abstract

OBJECTIVE:

Glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control and cardiometabolic risk factors in adults with type 2 diabetes mellitus, but pediatric data is sparse.

RESEARCH DESIGN AND METHODS:

This is the first report to describe the effects of GLP-1 receptor agonist Exenatide on metabolic risk and weight in adolescents with morbid obesity (BMI>35kg/m2) and type 2 diabetes in the first 6 months after treatment initiation. Two patients with morbid obesity who failed conventional therapy with insulin glargine and Metformin were treated with the addition of Exenatide. Metabolic parameters were obtained at 3 and 6 months post intervention.

RESULTS:

Improvements in cardiometabolic risk factors, such as fasting glucose and triglyceride levels, as well as HbA1c, were reached at 6 months compared to baseline.

CONCLUSIONS:

Our cases highlight the therapeutic potential of exenatide for adolescent patients with morbid obesity and type 2 diabetes.

KEYWORDS:

Adolescents; Exenatide; Obesity; Type 2 diabetes

PMID:
27182560
PMCID:
PMC4864000

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center